Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 13, 2000Journal of Clinical Oncology

Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJoachim von PawelAsklepios Fachkliniken München-GautingRRReinhard von RoemelingCuradel (United States)UGU. GatzemeierOntario Institute for Cancer Research

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pawel et al. (2000) studied this question.

synapsesocial.com/papers/6a9feb15fe80d3ecfb7c6ef7https://doi.org/10.1200/jco.2000.18.6.1351
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells1986 · 397 citations
  2. 2Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.1998 · 567 citations
  3. 3Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer2000 · 227 citations
  4. 4Cancer statistics, 19981998 · 2,384 citations
  5. 5Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer1997 · 61 citations